Kymera Therapeutics, Inc.
KYMR
$117.39
$2.972.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 89.15% | 1,097.39% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 89.15% | 1,097.39% | |||
| Cost of Revenue | 21.72% | 17.10% | |||
| Gross Profit | 14.60% | 21.20% | |||
| SG&A Expenses | 3.78% | 20.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 18.64% | 17.62% | |||
| Operating Income | 10.16% | 14.04% | |||
| Income Before Tax | 11.59% | 20.40% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 11.59% | 20.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 11.59% | 20.40% | |||
| EBIT | 10.16% | 14.04% | |||
| EBITDA | 9.32% | 15.73% | |||
| EPS Basic | 12.16% | 26.63% | |||
| Normalized Basic EPS | 12.17% | 26.61% | |||
| EPS Diluted | 12.16% | 26.63% | |||
| Normalized Diluted EPS | 12.17% | 26.61% | |||
| Average Basic Shares Outstanding | 0.66% | 8.47% | |||
| Average Diluted Shares Outstanding | 0.66% | 8.47% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||